These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1000 related articles for article (PubMed ID: 18774912)

  • 1. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial.
    Hauswirth WW; Aleman TS; Kaushal S; Cideciyan AV; Schwartz SB; Wang L; Conlon TJ; Boye SL; Flotte TR; Byrne BJ; Jacobson SG
    Hum Gene Ther; 2008 Oct; 19(10):979-90. PubMed ID: 18774912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years.
    Jacobson SG; Cideciyan AV; Ratnakaram R; Heon E; Schwartz SB; Roman AJ; Peden MC; Aleman TS; Boye SL; Sumaroka A; Conlon TJ; Calcedo R; Pang JJ; Erger KE; Olivares MB; Mullins CL; Swider M; Kaushal S; Feuer WJ; Iannaccone A; Fishman GA; Stone EM; Byrne BJ; Hauswirth WW
    Arch Ophthalmol; 2012 Jan; 130(1):9-24. PubMed ID: 21911650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety in nonhuman primates of ocular AAV2-RPE65, a candidate treatment for blindness in Leber congenital amaurosis.
    Jacobson SG; Boye SL; Aleman TS; Conlon TJ; Zeiss CJ; Roman AJ; Cideciyan AV; Schwartz SB; Komaromy AM; Doobrajh M; Cheung AY; Sumaroka A; Pearce-Kelling SE; Aguirre GD; Kaushal S; Maguire AM; Flotte TR; Hauswirth WW
    Hum Gene Ther; 2006 Aug; 17(8):845-58. PubMed ID: 16942444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Restoration of vision in RPE65-deficient Briard dogs using an AAV serotype 4 vector that specifically targets the retinal pigmented epithelium.
    Le Meur G; Stieger K; Smith AJ; Weber M; Deschamps JY; Nivard D; Mendes-Madeira A; Provost N; Péréon Y; Cherel Y; Ali RR; Hamel C; Moullier P; Rolling F
    Gene Ther; 2007 Feb; 14(4):292-303. PubMed ID: 17024105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial.
    Bennett J; Wellman J; Marshall KA; McCague S; Ashtari M; DiStefano-Pappas J; Elci OU; Chung DC; Sun J; Wright JF; Cross DR; Aravand P; Cyckowski LL; Bennicelli JL; Mingozzi F; Auricchio A; Pierce EA; Ruggiero J; Leroy BP; Simonelli F; High KA; Maguire AM
    Lancet; 2016 Aug; 388(10045):661-72. PubMed ID: 27375040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial.
    Maguire AM; High KA; Auricchio A; Wright JF; Pierce EA; Testa F; Mingozzi F; Bennicelli JL; Ying GS; Rossi S; Fulton A; Marshall KA; Banfi S; Chung DC; Morgan JI; Hauck B; Zelenaia O; Zhu X; Raffini L; Coppieters F; De Baere E; Shindler KS; Volpe NJ; Surace EM; Acerra C; Lyubarsky A; Redmond TM; Stone E; Sun J; McDonnell JW; Leroy BP; Simonelli F; Bennett J
    Lancet; 2009 Nov; 374(9701):1597-605. PubMed ID: 19854499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene therapy following subretinal AAV5 vector delivery is not affected by a previous intravitreal AAV5 vector administration in the partner eye.
    Li W; Kong F; Li X; Dai X; Liu X; Zheng Q; Wu R; Zhou X; Lü F; Chang B; Li Q; Hauswirth WW; Qu J; Pang JJ
    Mol Vis; 2009; 15():267-75. PubMed ID: 19190735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Canine and human visual cortex intact and responsive despite early retinal blindness from RPE65 mutation.
    Aguirre GK; Komáromy AM; Cideciyan AV; Brainard DH; Aleman TS; Roman AJ; Avants BB; Gee JC; Korczykowski M; Hauswirth WW; Acland GM; Aguirre GD; Jacobson SG
    PLoS Med; 2007 Jun; 4(6):e230. PubMed ID: 17594175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Long-Term Efficacy of AAV4 Gene Therapy in Patients with RPE65 Leber Congenital Amaurosis.
    Le Meur G; Lebranchu P; Billaud F; Adjali O; Schmitt S; Bézieau S; Péréon Y; Valabregue R; Ivan C; Darmon C; Moullier P; Rolling F; Weber M
    Mol Ther; 2018 Jan; 26(1):256-268. PubMed ID: 29033008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results at 5 Years After Gene Therapy for RPE65-Deficient Retinal Dystrophy.
    Pennesi ME; Weleber RG; Yang P; Whitebirch C; Thean B; Flotte TR; Humphries M; Chegarnov E; Beasley KN; Stout JT; Chulay JD
    Hum Gene Ther; 2018 Dec; 29(12):1428-1437. PubMed ID: 29869534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene therapy in the second eye of RPE65-deficient dogs improves retinal function.
    Annear MJ; Bartoe JT; Barker SE; Smith AJ; Curran PG; Bainbridge JW; Ali RR; Petersen-Jones SM
    Gene Ther; 2011 Jan; 18(1):53-61. PubMed ID: 20703309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results at 2 Years after Gene Therapy for RPE65-Deficient Leber Congenital Amaurosis and Severe Early-Childhood-Onset Retinal Dystrophy.
    Weleber RG; Pennesi ME; Wilson DJ; Kaushal S; Erker LR; Jensen L; McBride MT; Flotte TR; Humphries M; Calcedo R; Hauswirth WW; Chulay JD; Stout JT
    Ophthalmology; 2016 Jul; 123(7):1606-20. PubMed ID: 27102010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In utero gene therapy rescues vision in a murine model of congenital blindness.
    Dejneka NS; Surace EM; Aleman TS; Cideciyan AV; Lyubarsky A; Savchenko A; Redmond TM; Tang W; Wei Z; Rex TS; Glover E; Maguire AM; Pugh EN; Jacobson SG; Bennett J
    Mol Ther; 2004 Feb; 9(2):182-8. PubMed ID: 14759802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of subretinal readministration of a viral vector in large animals to treat congenital blindness.
    Amado D; Mingozzi F; Hui D; Bennicelli JL; Wei Z; Chen Y; Bote E; Grant RL; Golden JA; Narfstrom K; Syed NA; Orlin SE; High KA; Maguire AM; Bennett J
    Sci Transl Med; 2010 Mar; 2(21):21ra16. PubMed ID: 20374996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year.
    Cideciyan AV; Hauswirth WW; Aleman TS; Kaushal S; Schwartz SB; Boye SL; Windsor EA; Conlon TJ; Sumaroka A; Pang JJ; Roman AJ; Byrne BJ; Jacobson SG
    Hum Gene Ther; 2009 Sep; 20(9):999-1004. PubMed ID: 19583479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical gene therapy for the treatment of RPE65-associated Leber congenital amaurosis.
    Stein L; Roy K; Lei L; Kaushal S
    Expert Opin Biol Ther; 2011 Mar; 11(3):429-39. PubMed ID: 21299439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics.
    Cideciyan AV; Aleman TS; Boye SL; Schwartz SB; Kaushal S; Roman AJ; Pang JJ; Sumaroka A; Windsor EA; Wilson JM; Flotte TR; Fishman GA; Heon E; Stone EM; Byrne BJ; Jacobson SG; Hauswirth WW
    Proc Natl Acad Sci U S A; 2008 Sep; 105(39):15112-7. PubMed ID: 18809924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of blindness in animal models of leber congenital amaurosis using optimized AAV2-mediated gene transfer.
    Bennicelli J; Wright JF; Komaromy A; Jacobs JB; Hauck B; Zelenaia O; Mingozzi F; Hui D; Chung D; Rex TS; Wei Z; Qu G; Zhou S; Zeiss C; Arruda VR; Acland GM; Dell'Osso LF; High KA; Maguire AM; Bennett J
    Mol Ther; 2008 Mar; 16(3):458-65. PubMed ID: 18209734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene therapeutic prospects in early onset of severe retinal dystrophy: restoration of vision in RPE65 Briard dogs using an AAV serotype 4 vector that specifically targets the retinal pigmented epithelium.
    Rolling F; Le Meur G; Stieger K; Smith AJ; Weber M; Deschamps JY; Nivard D; Mendes-Madeira A; Provost N; Péréon Y; Cherel Y; Ali RR; Hamel C; Moullier P; Rolling F
    Bull Mem Acad R Med Belg; 2006; 161(10-12):497-508; discussion 508-9. PubMed ID: 17503728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of gene transfer for Leber's congenital amaurosis.
    Maguire AM; Simonelli F; Pierce EA; Pugh EN; Mingozzi F; Bennicelli J; Banfi S; Marshall KA; Testa F; Surace EM; Rossi S; Lyubarsky A; Arruda VR; Konkle B; Stone E; Sun J; Jacobs J; Dell'Osso L; Hertle R; Ma JX; Redmond TM; Zhu X; Hauck B; Zelenaia O; Shindler KS; Maguire MG; Wright JF; Volpe NJ; McDonnell JW; Auricchio A; High KA; Bennett J
    N Engl J Med; 2008 May; 358(21):2240-8. PubMed ID: 18441370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.